A year-long home-based study of 119 participants demonstrates that individuals with mild Alzheimer's disease can reliably self-administer frequent brain health assessments using a wireless EEG headset and cognitive task platform, achieving 99.7% completion rates and generating high-frequency data that may accelerate clinical trial design and reduce costs.
Key Points
- Participants with mild Alzheimer's completed 99.7% of initiated assessments over 52 weeks
- Frequent home-based measurements capture daily disease fluctuations missed by quarterly clinic visit
- High adherence enables smaller, shorter, less costly trials with stronger statistical power
Longevity Analysis
Early detection and tracking of cognitive decline relies on consistent, high-frequency biomarker collection—a challenge that clinic-based protocols have failed to solve. This research demonstrates that decentralized measurement systems can preserve data quality while removing the friction that causes dropout in aging populations. The ability to detect subtle day-to-day changes in brain function creates a foundation for interventions that respond to actual disease trajectory rather than delayed snapshots, compressing the timeline between treatment initiation and evidence of response. For clinical research broadly, this model suggests that accessibility and consistency—not just enrollment volume—drive statistical power and therapeutic discovery.
Original published by Longevity.Technology, by Kyle Umipig.